‘Deeply Troubling’ – Pharma Industry's Verdict On EU Compulsory Licensing Plan
The European Commission’s plans for an EU-wide compulsory licensing mechanism have drawn a wide range of responses, with some stakeholders wanting the whole idea dropped and others applauding it and calling for the mechanism to be used outside health emergency situations too.
You may also be interested in...
In an environment replete with pricing and patient access pressures, top biopharma companies are building commercialization models that emphasize inclusive and diverse decision-making and that integrate digital tools with a human salesforce.
The forthcoming unitary patent system and Unified Patent Court promise to make applying for patents in Europe and litigating infringements simpler and less costly for applicants.
The European Commission says its proposals on EU-level compulsory licensing and a unitary supplementary protection certificate will create a more efficient and future-proof framework for intellectual property rights.